CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 144 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2016. The put-call ratio across all filers is 0.75 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $982,000 | -46.9% | 421,402 | -35.3% | 0.00% | 0.0% |
| Q4 2017 | $1,850,000 | +71.1% | 651,531 | +72.3% | 0.00% | 0.0% |
| Q3 2017 | $1,081,000 | +39.1% | 378,098 | +20.2% | 0.00% | 0.0% |
| Q2 2017 | $777,000 | -16.1% | 314,485 | +22.6% | 0.00% | 0.0% |
| Q1 2017 | $926,000 | -6.0% | 256,576 | -7.7% | 0.00% | 0.0% |
| Q4 2016 | $985,000 | -15.9% | 278,108 | -4.1% | 0.00% | 0.0% |
| Q3 2016 | $1,171,000 | -33.6% | 289,900 | -27.8% | 0.00% | 0.0% |
| Q2 2016 | $1,763,000 | +31.1% | 401,595 | +12.8% | 0.00% | 0.0% |
| Q1 2016 | $1,345,000 | -76.5% | 355,901 | -2.7% | 0.00% | -75.0% |
| Q4 2015 | $5,734,000 | +43.5% | 365,686 | -3.5% | 0.00% | +33.3% |
| Q3 2015 | $3,996,000 | -59.4% | 379,090 | -2.9% | 0.00% | -57.1% |
| Q2 2015 | $9,848,000 | -8.1% | 390,464 | +1.5% | 0.01% | 0.0% |
| Q1 2015 | $10,717,000 | +57.7% | 384,532 | +3.3% | 0.01% | +40.0% |
| Q4 2014 | $6,796,000 | +35.1% | 372,373 | -4.1% | 0.01% | +25.0% |
| Q3 2014 | $5,031,000 | -22.9% | 388,226 | -3.0% | 0.00% | -20.0% |
| Q2 2014 | $6,529,000 | -4.3% | 400,040 | +3.6% | 0.01% | 0.0% |
| Q1 2014 | $6,824,000 | -28.1% | 386,200 | -1.5% | 0.01% | -28.6% |
| Q4 2013 | $9,491,000 | -28.8% | 392,040 | +4.2% | 0.01% | -30.0% |
| Q3 2013 | $13,333,000 | +120.4% | 376,320 | -2.9% | 0.01% | +100.0% |
| Q2 2013 | $6,050,000 | – | 387,587 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Byrne Asset Management LLC | 86 | $2,000 | 0.00% |